tbuckley/cabot-search huggingface dataset:
Incorrect Statement
Authors: Christine Schneyer, Ralph Shangraw, Stephen Sherman, Paul Englund
Journal: JAMA (1998)

Calcium Carbonate and Reduction of Levothyroxine EfficacyTo the Editor.-Iwould like to report an interaction between 2 commonly prescribed drugs, levothyroxine sodium and calcium carbonate, which reduces levothyroxine efficacy.This inhibition may be reversed by separating the administration of these 2 medications.In a recent evaluation of 3 women with thyroid cancer who were receiving levothyroxine to suppress serum thyroid-stimulating hormone (TSH) levels, it was noted that simultaneous ingestion of some calcium formulations reduced levothyroxine effectiveness (Table ).For example, patient 1 took levothyroxine (125 µg/d) and had a baseline serum TSH concentration of 0.08 mU/L (normal, 0.5-4.0mU/L).She subsequently began to take calcium carbonate (in the form of Tums) for prevention of osteoporosis, often taking it together with levothyroxine.She experienced fatigue and a 4.5-kg weight gain over the next 5 months, and her serum TSH level was found to have risen to 13.3 mU/L.She then stopped taking calcium carbonate but maintained her levothyroxine regimen.Three weeks later her serum TSH level had declined to 0.68 mU/L.In patients 2 and 3 (Table ), there was also loss of efficacy of levothyroxine when it was taken simultaneously with oyster shell calcium carbonate (in the form of Os-Cal).In both patients, levothyroxine activity was restored by administering it in the morning and administering calcium carbonate after lunch and dinner.Interestingly, patient 3 previously took a different form of calcium carbonate (Giant brand) with levothyroxine without affecting TSH suppression.Decreased bioavailability induced by simultaneous intake of other medications (eg, aluminum-containing antacids, iron, cholestyramine, sucralfate) is a well-known occurrence with levothyroxine therapy. 1 Decreased absorption could similarly account for the calcium carbonate effect.Calcium carbonate itself or, alternatively, excipients or contaminants in the preparation 2 could form insoluble chelates with levothyroxine. 3 Differences in excipients or contaminants or variations in rates of dissolution 2 could explain the discrepant effects of the 2 calcium carbonate preparations used by patient 3.Given that both calcium and levothyroxine are used together in a large number of patients, this phenomenon is likely to be widespread.Special attention should be directed toward postmenopausal women, as these individuals most frequently use calcium supplements to prevent osteoporosis and, in addition, often require therapy with levothyroxine. 4 Separating administration of these medications by at least 4 hours should provide a simple method for maintaining levothyroxine efficacy.
Abstract P6-07-07: ESR1 amplification and 5'-3' exon imbalance in metastatic breast cancer
Authors: S Oesterreich, A Basudan, N Preideigkeit, RJ Hartmaier, A Bahreini, R Gyanchandani, JP Leone, PC Lucas, RL Hamilton, AM Brufsky, AV Lee
Journal: Cancer Research (2017)

Abstract BACKGROUND: Growing evidence indicates that base pair mutations in ESR1 are relatively uncommon in newly diagnosed, treatment-naive breast cancer, but frequently acquired in hormone-resistant metastatic breast cancer (MBC). We and others have recently identified ESR1 gene fusion and amplification in MBC, with the ESR1 fusions generally encompassing AF1 and the DNA binding domain. The genomic break required for gene fusions often results in an imbalance in the DNA copy number of exons around the break. We examined ESR1 amplification and 5' and 3' exon copy number imbalance in MBC. MATERIALS and METHODS: We designed NanoString DNA hybridization probes against coding and non-coding exons (n=9) in ESR1 and 15 reference probes. We analyzed 128 samples consisting of 61 ER-positive and 44 ER-negative metastases, and 23 primary breast cancers. DNA copy number (CN) was determined using nSolver, with &amp;gt;2.7CN as copy number gain, and &amp;gt;10 as CN amplification. ESR1 CN was calculated by averaging the DNA copy number obtained from all coding exons. The 5'-3' copy number ratio was the average copy number of the 5' exons (3-6) divided by the 3' exons (7-10). RESULTS: 8 (13%) ER positive metastatic breast cancers showed ESR1 amplification with 5 (8%) having &amp;gt;2.7CN, and 3 (5%) with &amp;gt;10CN. In contrast, in ER-negative metastases, we did not detect any samples with amplification &amp;gt;10CN, and a gain (&amp;gt;2.7 CN) in one case. Similarly, in ER+ primary cancers we did not detect any samples with &amp;gt;10 CN amplifications and 2 samples with CN gain (&amp;gt;2.7 CN). ESR1 showed 5'-3' CN imbalance in 1 primary (5%) and in 5 metastatic (5%) breast cancers. We are currently confirming and expanding these data in a larger dataset. CONCLUSIONS: In addition to ESR1 mutations, ESR1 CN amplifications and 5'-3' imbalance are represent frequent occurrences in endocrine resistant breast cancer. Future studies are aimed at understanding whether the observed exon imbalances are associated with generation of fusion proteins, and whether and how ESR1 amplifications cause changes in endocrine treatment response. Citation Format: Oesterreich S, Basudan A, Preideigkeit N, Hartmaier RJ, Bahreini A, Gyanchandani R, Leone JP, Lucas PC, Hamilton RL, Brufsky AM, Lee AV. ESR1 amplification and 5'-3' exon imbalance in metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P6-07-07.
The Relationship of Acute Gvhd and Pre- and Post-Transplant Flow-MRD to the Incidence and Timing of Relapse in Children Undergoing Allogeneic Transplantation for High Risk ALL: Defining a Target Population and Window for Immunological Intervention to Prevent Relapse
Authors: Michael A. Pulsipher, Bryan Langholz, Donna A. Wall, Kirk R. Schultz, Nancy Bunin, Julie M. Gastier-Foster, Michael J. Borowitz, Rakesh Goyal, Sharon Gardner, William L. Carroll, Elizabeth Raetz, Stephan A. Grupp
Journal: Blood (2012)
A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.
Authors: Kyle J MacBeth, Eric Laille, Yuhong Ning, Christopher R. Cogle, Barry Skikne, Steven D. Gore, Guillermo Garcia-Manero, M. Renee Ward
Journal: Blood (2009)
Good but Variable Humoral Response to Trivalent Influenza Vaccination in Patients with Non-Hodgkin’s Lymphoma - Two Seasons Experience.
Authors: Piotr Centkowski, Lidia Brydak, Magdalena Machala, Ewa Kalinka, Maria Blasinska-Morawiec, Joanna Wegrzyn, Aleksander Skotnicki, Irena Federowicz, Jan Walewski, Dariusz Wolowiec, Joanna Sawczuk-Chabin, Przemyslaw Bilinski, Krzysztof Warzocha
Journal: Blood (2005)
The 10-Item Sickle Cell Disease Severity Measure (SCDSM-10): A Novel Measure of Daily SCD Symptom Severity Developed to Assess Benefit of GBT440, an Experimental HbS Polymerization Inhibitor
Authors: Laurie Burke, Jeremy Charles Hobart, Kathleen Fox, Josh Lehrer-Graiwer, Kenneth Bridges, Martine Kraus, Eleanor Ramos
Journal: Blood (2016)
Prognostic Value of Molecular Markers for Guiding Post-Remission Therapy in Patients with De Novo Acute Myeloid Leukemia (AML) and Intermediate-Risk Cytogenetics
Authors: Marta Pratcorona, Mireia Camós, Montserrat Torrebadell, Maria Rozman, Ana Carrió, Dolors Costa, Alexandra Valera, Elias Campo, Emili Montserrat, Jordi Esteve
Journal: Blood (2008)
Medicare reimbursement accuracy under the prospective payment system, 1985 to 1988
Authors: D. C. Hsia
Journal: JAMA (1992)

<h3>Background.</h3> —Hospital reimbursement by Medicare's prospective payment system depends on accurate identification and coding of inpatients' diagnoses and procedures using the<i>International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM</i>). A previous study showed that 20.8%±0.5% (mean±SE) of hospital bills for 1985 contained errors that changed their diagnosis related group (DRG) and that a significant 61.6%±1.3% of errors overreimbursed the hospitals. This DRG "creep" improperly increased net reimbursement by 1.9%, $308 million when projected nationally. The present study updated our previous study with 1988 data. <h3>Methods.</h3> —The Office of Inspector General, US Department of Health and Human Services, obtained a simple random sample of 2451 hospital charts for Medicare discharges from 1988. The American Medical Record Association reabstracted the<i>ICD-9-CM</i>codes on a blinded basis, grouped them to DRGs, and determined the reasons for discrepancies. <h3>Results.</h3> —Coding errors declined to 14.7%±0.7% in 1988, and a nonsignificant 50.7%±2.6% of DRG errors overreimbursed the hospitals. Projected nationally, hospitals did not receive a significant overreimbursement. Physician misspecification of the narrative diagnoses underreimbursed the hospitals, while billing department resequencing overreimbursed them. <h3>Conclusions.</h3> —The attestation requirement may have deterred DRG creep due to attending physician upcoding, but the peer review organizations' sentinel effect and educational activities have not eliminated hospital resequencing. (<i>JAMA</i>. 1992;268:896-899)
Abstract P5-08-21: The effect of family history on screening procedures and prognosis in breast cancer patients – Results of a large population-based case–control study on breast cancer
Authors: K Seiffert, K Thoene, C zu Eulenburg, A Rudolph, B Schmalfeldt, D Flesch-Janys, J Chang-Claude, I Witzel
Journal: Cancer Research (2017)

Abstract Background: Patients with a first- or second-degree family history of breast or ovarian cancer participate more frequently in breast cancer screening procedures. A benefit of additional screening visits has been documented in high-risk patients with (e.g. BRCA 1, BRCA 2 gene mutations). However, the potential benefit of additional screening examinations in moderate risk patients (patients with a history of breast cancer in one or two family members) remains unclear. Methods: Patients were recruited in 2002–2005 within a large population-based case–control study on breast cancer in Germany (3,813 cases and 7,341 age-matched healthy controls). Univariate and multivariate analyses were performed to evaluate the effect of family history on breast cancer risk, participation in screening procedures, tumor size and prognosis. Results A higher breast cancer risk was observed in patients with a positive family history (1 affected family member: OR 1.32, p&amp;lt;0.001). Patients with a 1st degree positive family history received a higher number of mammograms (MG) (&amp;gt;10 MG: 42.7% vs. 24.9%, p&amp;lt;0.001) and showed a higher rate of imaging-detected tumors (mammogram or ultrasound) (45.8% vs. 31.9%, p&amp;lt;0.001) compared to patients without positive family history. Positive family history (OR 1.45 pT1 vs. ≥pT2, p&amp;lt;0.001) and higher number of mammograms (≥10 mammograms: OR 2.29 pT1 vs. ≥pT2) were associated with smaller tumor size at initial diagnosis. Additionally, there was a significant association between mammogram regularity (HR 0.72, p&amp;lt;0.001) and imaging-assisted tumor detection (HR 0.66, p&amp;lt;0.001) with improved overall survival. However, no significant association between a positive family history of breast cancer and survival could be seen. Discussion: Patients with a family history of breast cancer participated more frequently in screening procedures and had a higher rate of image-detected tumors with smaller size at initial diagnosis, compared to patients without affected family members. Breast cancer screening procedures were significantly associated with improved survival. Citation Format: Seiffert K, Thoene K, zu Eulenburg C, Rudolph A, Schmalfeldt B, Flesch-Janys D, Chang-Claude J, Witzel I. The effect of family history on screening procedures and prognosis in breast cancer patients – Results of a large population-based case–control study on breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-08-21.
“Step-Up Approach” for the Treatment of Postoperative Severe Pancreatic Fistula
Authors: Elena Rangelova, Roberto Valente, Marco Del Chiaro
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Triterpene Glycosides from Cimicifuga FoetidaRegulate wnt/β-Catenin Signaling in Human KG-1a Leukemia Cells
Authors: Rui-Rong Xu, Si-Yuan Cui, Chong Chen, Ning Jiao, Xiao-Long Wu, Xin Wang, Ming-Hua Qiu
Journal: Blood (2016)
Abstract P5-11-11: A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA)
Authors: SB Goldfarb, J Konner, J Stevens, S Brouwer, NR Narain, R Ye, S Ravipaty, R Sarangarajan, VR Akmaev, JJ Jimenez, VR Belum, S 'Kitts, K Ciccolini, B Berman, ME Lacouture
Journal: Cancer Research (2017)

Abstract Background: Chemotherapy induced alopecia (CIA) may lead to significant psychosocial and quality of life issues. Currently there are no FDA approved oral or topical agents available to prevent CIA. In murine studies, topical calcitriol reduced CIA, due to arrest of cell cycle in healthy hair follicles, and reduction in the sensitivity of follicular epithelium to chemotherapy. Methods: A prospective dose escalation study is being performed in up to 31 women with breast cancer, gynecologic cancer and sarcomas. Each patient is applying 1mL of BPM31543 to her scalp bid, ≥ 5 days prior to initiation of taxane-based chemotherapy for at least 3 months or until the completion of chemotherapy. The study cohorts are: 5/10/20/40/60/80μg/mL. The first 5 cohorts are completely enrolled and the final cohort is currently being enrolled. Each patient undergoes pk analysis, adverse event (AE) monitoring, patient self-assessment diaries (1-10 scale), and blinded photographic assessments. Efficacy and pK data are still being collected and analyzed for the patients on study, but will be available by December. Results: Twenty-four subjects have been enrolled so far (evaluable at this time, n = 13). Pk data (n = 16; 5-40μg/mL) showed inter-individual variability, but no significant dose-dependent increase in systemic absorption (range, &amp;lt; 20-110 pg/mL). Treatment-related AEs (probably/possibly) were mild/moderate in nature and included scalp pain (n = 1; 5 μg/mL), elevated vitamin D levels in 1 patient (20μg/mL) and passage of renal calculus in another (n = 1; 40μg/mL). All subjects reported changes in overall hair fullness, thickness, and volume of hair during chemotherapy. At the 5/10 μg/mL dose level, ≥ 75% hair loss was reported in 85% of patients. At the ≥ 20 μg/mL dose level, ≥ 75% hair loss was seen only in 43% of patients. Hair loss/ thinning caused all subjects to change their hair style (onset, week 2; peak, weeks 5-6). Conclusions: Data have shown that the twice daily application of BPM31543 in patients receiving taxane-based chemotherapy was safe and well-tolerated. Efficacy data from the preliminary analysis was promising and led to the amendment of the study to evaluate two additional higher dose cohorts: 60 and 80 μg/ml. Citation Format: Goldfarb SB, Konner J, Stevens J, Brouwer S, Narain NR, Ye R, Ravipaty S, Sarangarajan R, Akmaev VR, Jimenez JJ, Belum VR, 'Kitts S, Ciccolini K, Berman B, Lacouture ME. A phase I safety study of topical calcitriol (BPM31543) for the prevention of chemotherapy-induced alopecia (CIA) [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-11-11.
Cyclopamine Induced Apoptosis in Primary CD34+ Acute Leukemic Cells.
Authors: Masayoshi Kobune, Kazuyuki Murase, Satoshi Iyama, Tsutomu Sato, Rishu Takimoto, Yutaka Kawano, Shohei Kikuchi, Koji Miyanishi, Yasushi Sato, Junji Kato
Journal: Blood (2009)
Letter by Nadir Regarding Article, “Optical Coherence Tomography to Optimize Results of Percutaneous Coronary Intervention in Patients With Non-ST-Elevation Acute Coronary Syndrome: Results of the Multicenter, Randomized DOCTORS Study (Does Optical Coherence Tomography Optimize Results of Stenting)”
Authors: M. Adnan Nadir
Journal: Circulation (2017)
Lost and Gain of t(4;14) and t(11;14) in Multiple Myeloma Patients Between Relapse and diagnosis: An Illustration of Clonal Dynamic During Disease Course. an IFM Study
Authors: Benjamin Hebraud, Denis Caillot, Jill Corre, Gerald Marit, Cyrille Hulin, Xavier Leleu, Marc Wetterwald, Mamoun Dib, Philippe Rodon, Laurent Voillat, Bruno Royer, Eric G. Voog, Anne-Marie Stoppa, Laurent Garderet, Brigitte Kolb, Michel Maigre, Boullanger FOW HENG Nadine, Olivier Allangba, Thierry Facon, Claire Mathiot, Michel Attal, Philippe Moreau, Herve avet-Loiseau
Journal: Blood (2012)
Molecular Classification of Multiple Myeloma (MM) Based on Gene Expression Profiling (GEP) and Fluorescence In Situ Hybridisation (FISH) Is an Independent Predictor for Event Free Survival (EFS).
Authors: Dirk Hose, Jean-François Rossi, Carina Ittrich, John De Vos, Thierry Rème, Axel Benner, Karène Mahtouk, Coral del Val, Jérôme Moreaux, Agnes Hotz-Wagenblatt, Sunitha Jonnakut, Marc Raab, Philine Kaukel, Marion Moos, Veronique Grau, Anna Jauch, Eric Jourdan, Friedrich W. Cremer, Bernard Klein, Hartmut Goldschmidt
Journal: Blood (2005)
TGF-β1 Supports Leukemia Cell Survival Via Negative Regulation of FLI-1 Transcription Factor, ERK Inactivation and MMP-1 Secretion
Authors: Yoko Tabe, Linhua Jin, Yasuhito Hatanaka, Takashi Miida, Steven M. Kornblau, Michael Andreeff, Marina Konopleva
Journal: Blood (2012)
Abstract P5-08-09: Use of oral contraceptives and risk of breast cancer in <i>BRCA1</i> and <i>BRCA2</i> mutation carriers: An international prospective cohort study; for the studies of EMBRACE, GENEPSO, HEBON, kConFab and BCFR
Authors: LH Schrijver, H Olsson, AC Antoniou, RL Milne, K-A Phillips, N Andrieu, DF Easton, D Goldgar, C Engel, K Kast, M-J Roos-Blom, TM Mooij, JL Hopper, FE van Leeuwen, M-B Terry, MA Rookus
Journal: Cancer Research (2017)

Abstract This abstract was withdrawn by the authors.
Abstract 388: High-throughput Single Cell Tracking of Mitochondrial Function in Cardiomyocytes
Authors: Giovanni Fajardo, Kristi Bezold, Tobias Meyer, Daria Mochly-Rosen, Daniel Bernstein
Journal: Circulation Research (2015)

Mitochondria play a significant role in the regulation of multiple functions in the heart, ranging from metabolism to cell death. Most mitochondrial assays require either isolating the organelle, thus disrupting the intracellular signaling or using intact cells with average measurements for the entire population neglecting the ability to distinguish cell heterogeneity. Here we describe a novel method for tracking single cell mitochondrial function in cell populations over time. Adult mouse myocytes were exposed to the mitochondrial uncoupler FCCP and hydrogen peroxide to induce changes in membrane potential and oxidative stress, respectively. TMRM and mitosox fluorescence were used to quantify mitochondrial membrane potential and ROS production, Fluo-4 fluorescence was used to assess intracellular calcium. Tracking of single cells was performed using Matlab and Imaris software. After FCCP exposure TMRM signal intensity decreased before there was a significant change in myocyte length that led to hypercontracture and cell death within 10 minutes. To better understand the dynamics of mitochondrial function and its relationship with cell death a dose response curve was established for hydrogen peroxide at 100, 500 and 1000 μM. The higher doses of hydrogen peroxide induced hypercontracture faster than lower doses. For further studies 100 μM was used to assess how homogenous the response to hydrogen peroxide was in cell populations. We found 3 distinct populations of cells responding at different times, a population of cells hypercontracted between 7-10 min, another between 10-15 min and a third population only after 15 min. Changes in membrane potential, oxidative stress and intracellular calcium were simultaneously assessed for every single cell during these time points. In addition, given the organized structure of the mitochondria in the myocyte we have adapted our technique to track individual mitochondria to study heterogeneous responses at the single mitochondrion level. This method provides a unique tool to simultaneously assess multiple parameters of mitochondrial function in single cells over time. In doing so, we have unmasked a complex heterogeneity of single cell behavior that is lost in methods than only average cell populations.
Effect of 5-Azacytidine (5-AzaC) In the Expression of PRAME In Acute Myeloid Leukemia (AML)
Authors: Silvia Gutiérrez Cosío, Esteban Ballestar, Carlos Santamaría, Belen Blanco, Luis Ignacio Sánchez Abarca, Teresa Caballero Velázquez, Carmen Herrero Sánchez, Soraya Carrancio, Laura Ciudad, Consuelo Cañizo, Jesus F San Miguel, Jose Antonio Pérez Simón
Journal: Blood (2010)
Substance Use Terminology
Authors: Anthony I. Barnett, Wayne Hall, Adrian Carter
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal